Literature DB >> 29932374

Endovascular treatment for emergent large vessel occlusion due to severe intracranial atherosclerotic stenosis.

Dong-Hun Kang1,2, Woong Yoon3, Seul Kee Kim3, Byung Hyun Baek3, Yun Young Lee3, Yong-Won Kim4, Yong-Sun Kim2, Yang-Ha Hwang4, Joon-Tae Kim5, Man Seok Park5.   

Abstract

OBJECTIVEThe optimal treatment strategy for patients with emergent large vessel occlusion (ELVO) due to underlying severe intracranial atherosclerotic stenosis (ICAS) is unclear. The purpose of this study was to compare treatment outcomes from intracranial angioplasty with or without stenting and intraarterial infusion of a glycoprotein IIb/IIIa inhibitor in patients with ELVO due to severe ICAS, and to investigate predictors of outcome after endovascular therapy in such patients.METHODSA total of 140 consecutive patients with ELVO attributable to severe ICAS underwent endovascular therapy at two stroke centers (A and B). Intracranial angioplasty/stenting was primarily performed at center A and intraarterial infusion of glycoprotein IIb/IIIa inhibitor (tirofiban) at center B. Data from both centers were prospectively collected into a database and retrospectively analyzed.RESULTSOverall, successful reperfusion was achieved in 95% (133/140) of patients and a good outcome in 60% (84/140). The mortality rate was 7.9%. Symptomatic hemorrhage occurred in 1 patient. There were no significant differences in the rates of successful reperfusion, symptomatic hemorrhage, 3-month modified Rankin scale score 0-2, and mortality between the two centers. Multivariate logistic regression analysis revealed the only independent predictor of good outcome was a history of previous stroke or transient ischemic attack (TIA) (odds ratio 0.254, 95% confidence interval 0.094-0.689, p = 0.007).CONCLUSIONSBoth intracranial angioplasty/stenting and intraarterial infusion of a glycoprotein IIb/IIIa inhibitor are effective and safe in the treatment of underlying severe ICAS in acute stroke patients with ELVO. In addition, a lack of a history of stroke/TIA was the only independent predictor of good outcome after endovascular therapy in such patients.

Entities:  

Keywords:  DWI = diffusion weighted imaging; ELVO = emergent large vessel occlusion; ICA = internal carotid artery; ICAS = intracranial atherosclerotic stenosis; IQR = interquartile range; IV = intravenous; MCA = middle cerebral artery; NIHSS = National Institutes of Health Stroke Scale; TIA = transient ischemic attack; WASID = Warfarin-Aspirin Symptomatic Intracranial Disease; atherosclerosis; cerebral infarction; intracranial; m-TICI = modified treatment in cerebral infarction; mRS = modified Rankin scale; percutaneous transluminal angioplasty; rt-PA = recombinant tissue plasminogen activator; thrombectomy; vascular disorders

Year:  2018        PMID: 29932374     DOI: 10.3171/2018.1.JNS172350

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  14 in total

1.  Endovascular treatment of acute intracranial vertebrobasilar artery occlusion: a multicenter retrospective observational study.

Authors:  Tao Quan; Haiman Hou; Wenjun Xue; Guangzhou Yu; Hengfei Ma; Jiachen Sun; Sheng Guan; Yuming Xu; Haowen Xu
Journal:  Neuroradiology       Date:  2019-09-04       Impact factor: 2.804

2.  Tirofiban for acute ischemic stroke: systematic review and meta-analysis.

Authors:  Jinhong Gong; Jingjing Shang; Hai Yu; Qian Wan; Dan Su; Zhiqiang Sun; Guangjun Liu
Journal:  Eur J Clin Pharmacol       Date:  2020-01-03       Impact factor: 2.953

3.  Direct angioplasty for acute ischemic stroke due to intracranial atherosclerotic stenosis-related large vessel occlusion.

Authors:  Guang Zhang; Yeping Ling; Shiyi Zhu; Pei Wu; Chunlei Wang; Jingtao Qi; Zhiyong Ji; Bingjie Zheng; Shancai Xu; Huaizhang Shi
Journal:  Interv Neuroradiol       Date:  2020-08-10       Impact factor: 1.610

4.  Refractory Stroke Thrombectomy: Prevalence, Etiology, and Adjunctive Treatment in a North American Cohort.

Authors:  R N Abdalla; D R Cantrell; A Shaibani; M C Hurley; B S Jahromi; M B Potts; S A Ansari
Journal:  AJNR Am J Neuroradiol       Date:  2021-04-22       Impact factor: 4.966

Review 5.  Current Opinion on Endovascular Therapy for Emergent Large Vessel Occlusion Due to Underlying Intracranial Atherosclerotic Stenosis.

Authors:  Dong Hun Kang; Woong Yoon
Journal:  Korean J Radiol       Date:  2019-05       Impact factor: 3.500

6.  CTA-Based Truncal-Type Occlusion Is Best Matched With Postprocedural Fixed Focal Stenosis in Vertebrobasilar Occlusions.

Authors:  Seong-Joon Lee; Ji Man Hong; Jin Wook Choi; Dong-Hun Kang; Yong-Won Kim; Yong-Sun Kim; Jeong-Ho Hong; Joonsang Yoo; Chang-Hyun Kim; Sung-Il Sohn; Yang-Ha Hwang; Jin Soo Lee
Journal:  Front Neurol       Date:  2019-01-21       Impact factor: 4.003

7.  Combination of Rescue Stenting and Antiplatelet Infusion Improved Outcomes for Acute Intracranial Atherosclerosis-Related Large-Vessel Occlusion.

Authors:  Jang-Hyun Baek; Cheolkyu Jung; Byung Moon Kim; Ji Hoe Heo; Dong Joon Kim; Hyo Suk Nam; Young Dae Kim; Eun Hyun Lim; Jun-Hwee Kim; Jun Yup Kim; Jae Hyoung Kim
Journal:  Front Neurol       Date:  2021-07-05       Impact factor: 4.003

8.  The Safety of Intra-arterial Tirofiban during Endovascular Therapy after Intravenous Thrombolysis.

Authors:  S H Jang; S-I Sohn; H Park; S-J Lee; Y-W Kim; J M Hong; C-H Kim; J W Choi; D-H Kang; Y-S Kim; Y-H Hwang; J S Lee; J-H Hong
Journal:  AJNR Am J Neuroradiol       Date:  2021-07-22       Impact factor: 4.966

9.  Effects of hypertension in patients receiving mechanical thrombectomy: A meta-analysis.

Authors:  Zhengzhou Yuan; Ning Chen; Muke Zhou; Jian Guo; Yanan Zhang; Yanbo Li; Li He
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

10.  Jet-Like Appearance in Angiography as a Predictive Image Marker for the Occlusion of Intracranial Atherosclerotic Stenosis.

Authors:  Xing Jin; Feina Shi; Yigang Chen; Xu Zheng; Jinhua Zhang
Journal:  Front Neurol       Date:  2020-10-30       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.